𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A “FOXO” in sight: Targeting Foxo proteins from conception to cancer

✍ Scribed by Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang; Jinling Hou


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
253 KB
Volume
29
Category
Article
ISSN
0198-6325

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

The successful treatment for multiple disease entities can rest heavily upon the ability to elucidate the intricate relationships that govern cellular proliferation, metabolism, survival, and inflammation. Here we discuss the therapeutic potential of the mammalian forkhead transcription factors predominantly in the O class, FoxO1, FoxO3, FoxO4, and FoxO6, which play a significant role during normal cellular function as well as during progressive disease. These transcription factors are integrated with several signal transduction pathways, such as Wnt proteins, that can regulate a broad array of cellular process that include stem cell proliferation, aging, and malignancy. FoxO transcription factors are attractive considerations for strategies directed against human cancer in light of their pro‐apoptotic effects and ability to lead to cell cycle arrest. Yet, FoxO proteins can be associated with infertility, cellular degeneration, and unchecked cellular proliferation. As our knowledge continues to develop for this novel family of proteins, potential clinical applications for the FoxO family should heighten our ability to limit disease progression without clinical compromise. © 2008 Wiley periodicals, Inc. Med Res Rev, 29, No. 3, 395‐418, 2009


📜 SIMILAR VOLUMES


Formatted anti–tumor necrosis factor α V
✍ Ken Coppieters; Torsten Dreier; Karen Silence; Hans De Haard; Marc Lauwereys; Pe 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 361 KB 👁 1 views

## Abstract ## Objective The advent of tumor necrosis factor (TNF)–blocking drugs has provided rheumatologists with an effective, but highly expensive, treatment for the management of established rheumatoid arthritis (RA). Our aim was to explore preclinically the application of camelid anti‐TNF VH